CovidChloroV1, Main, Corpus, bibRecord, 000541

Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.

Identifieur interne : 000541 ( Main/Corpus ); précédent : 000540; suivant : 000542

Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.

Auteurs : Luis Gabriel Parra-Lara ; Juan José Martinez-Arboleda ; Daniel Francisco Isaza-Pierotti ; Fernando Rosso

Source :

International journal of antimicrobial agents [ 1872-7913 ] ; 2021.

RBID : pubmed:33408017

English descriptors

KwdEn :
- Anti-Bacterial Agents (therapeutic use), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (drug therapy), COVID-19 (virology), Clinical Trials as Topic (MeSH), Drug Combinations (MeSH), Drug Repositioning (MeSH), Drug Synergism (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), SARS-CoV-2 (pathogenicity), Statistics as Topic (MeSH), Treatment Outcome (MeSH).
MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antimalarials, Antiviral Agents, Azithromycin, Hydroxychloroquine.
- drug therapy : COVID-19.
- pathogenicity : SARS-CoV-2.
- virology : COVID-19.
- Clinical Trials as Topic, Drug Combinations, Drug Repositioning, Drug Synergism, Humans, Statistics as Topic, Treatment Outcome.

DOI: 10.1016/j.ijantimicag.2020.106172
PubMed: 33408017
PubMed Central: PMC7779262

Links to Exploration step

pubmed:33408017

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.</title>
<author><name sortKey="Parra Lara, Luis Gabriel" sort="Parra Lara, Luis Gabriel" uniqKey="Parra Lara L" first="Luis Gabriel" last="Parra-Lara">Luis Gabriel Parra-Lara</name>
<affiliation><nlm:affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. Electronic address: luisgabrielparralara@hotmail.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Martinez Arboleda, Juan Jose" sort="Martinez Arboleda, Juan Jose" uniqKey="Martinez Arboleda J" first="Juan José" last="Martinez-Arboleda">Juan José Martinez-Arboleda</name>
<affiliation><nlm:affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Isaza Pierotti, Daniel Francisco" sort="Isaza Pierotti, Daniel Francisco" uniqKey="Isaza Pierotti D" first="Daniel Francisco" last="Isaza-Pierotti">Daniel Francisco Isaza-Pierotti</name>
<affiliation><nlm:affiliation>Harvard Medical School, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rosso, Fernando" sort="Rosso, Fernando" uniqKey="Rosso F" first="Fernando" last="Rosso">Fernando Rosso</name>
<affiliation><nlm:affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Infectious Diseases Service, Department of Internal Medicine, Fundación Valle del Lili, Cali, Colombia; Centro de Investigaciones Clínicas (CIC), Fundación Valle del Lili, Cali, Colombia.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33408017</idno>
<idno type="pmid">33408017</idno>
<idno type="doi">10.1016/j.ijantimicag.2020.106172</idno>
<idno type="pmc">PMC7779262</idno>
<idno type="wicri:Area/Main/Corpus">000541</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000541</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.</title>
<author><name sortKey="Parra Lara, Luis Gabriel" sort="Parra Lara, Luis Gabriel" uniqKey="Parra Lara L" first="Luis Gabriel" last="Parra-Lara">Luis Gabriel Parra-Lara</name>
<affiliation><nlm:affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. Electronic address: luisgabrielparralara@hotmail.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Martinez Arboleda, Juan Jose" sort="Martinez Arboleda, Juan Jose" uniqKey="Martinez Arboleda J" first="Juan José" last="Martinez-Arboleda">Juan José Martinez-Arboleda</name>
<affiliation><nlm:affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Isaza Pierotti, Daniel Francisco" sort="Isaza Pierotti, Daniel Francisco" uniqKey="Isaza Pierotti D" first="Daniel Francisco" last="Isaza-Pierotti">Daniel Francisco Isaza-Pierotti</name>
<affiliation><nlm:affiliation>Harvard Medical School, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rosso, Fernando" sort="Rosso, Fernando" uniqKey="Rosso F" first="Fernando" last="Rosso">Fernando Rosso</name>
<affiliation><nlm:affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Infectious Diseases Service, Department of Internal Medicine, Fundación Valle del Lili, Cali, Colombia; Centro de Investigaciones Clínicas (CIC), Fundación Valle del Lili, Cali, Colombia.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of antimicrobial agents</title>
<idno type="eISSN">1872-7913</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (virology)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Drug Combinations (MeSH)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Drug Synergism (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>SARS-CoV-2 (pathogenicity)</term>
<term>Statistics as Topic (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Drug Combinations</term>
<term>Drug Repositioning</term>
<term>Drug Synergism</term>
<term>Humans</term>
<term>Statistics as Topic</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33408017</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>57</Volume>
<Issue>1</Issue>
<PubDate><Year>2021</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>International journal of antimicrobial agents</Title>
<ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.</ArticleTitle>
<Pagination><MedlinePgn>106172</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30378-2</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.106172</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parra-Lara</LastName>
<ForeName>Luis Gabriel</ForeName>
<Initials>LG</Initials>
<AffiliationInfo><Affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. Electronic address: luisgabrielparralara@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martinez-Arboleda</LastName>
<ForeName>Juan José</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Isaza-Pierotti</LastName>
<ForeName>Daniel Francisco</ForeName>
<Initials>DF</Initials>
<AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rosso</LastName>
<ForeName>Fernando</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Infectious Diseases Service, Department of Internal Medicine, Fundación Valle del Lili, Cali, Colombia; Centro de Investigaciones Clínicas (CIC), Fundación Valle del Lili, Cali, Colombia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Antimicrob Agents</MedlineTA>
<NlmUniqueID>9111860</NlmUniqueID>
<ISSNLinking>0924-8579</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Antimicrob Agents. 2021 Jan;57(1):106237</RefSource>
<PMID Version="1">33408027</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Declaration of Competing Interest None</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>1</Month>
<Day>7</Day>
<Hour>5</Hour>
<Minute>53</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33408017</ArticleId>
<ArticleId IdType="pii">S0924-8579(20)30378-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106172</ArticleId>
<ArticleId IdType="pmc">PMC7779262</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000541 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000541 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33408017
   |texte=   Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33408017" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.

Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki